Michael Barbella, Managing Editor05.03.22
Orthofix Medical Inc. and MTF Biologics are expanding their orthobiologics partnership.
The collaboration extends Orthofix’s exclusive marketing rights to the Trinity allograft line through 2032 and includes an expansion agreement for the development of a demineralized bone matrix (DBM) that Orthofix will market under the Legacy brand name.
“Together Orthofix and MTF Biologics have a long history of bringing advanced biologic solutions to the market, with more than 350,000 patients receiving their Trinity allografts,” said Orthofix President of Global Spine Kevin Kenny. “This agreement solidifies our partnership with MTF Biologics as the sole provider of MTF allograft offerings. The addition of the Legacy demineralized bone line will expand our biologic portfolio, increasing the options available and offering a value solution for our customers and their patients.”
The Legacy DBM will be a complementary addition to the Orthofix demineralized bone line which consists of FiberFuse Advanced and FiberFuse Strip, both also provided by MTF Biologics. A demineralized cortical bone powder with a sodium hyaluronate carrier, the Legacy DBM will be applicable in spine and orthopedic procedures. The Parties expect to make the Legacy DBM available to customers starting in the third quarter.
Orthofix recognizes the important role of biologic solutions in spine and orthopedic surgical applications. In addition to the MTF Biologics allograft solutions, Orthofix markets and distributes the Opus Mg Set bone void filler, Opus BA bioactive bone graft, Collage osteoconductive scaffold, and the O-Genesis graft deliver system. This portfolio gives surgeons the ability to select the best option to meet their procedural and patient needs.
“MTF Biologics is pleased to strengthen our exclusive partnership with Orthofix to continue our joint investments in innovative solutions, and the provision of Trinity Elite and Trinity Evolution allografts,” said Joe Yaccarino, president and CEO MTF Biologics. “This agreement aligns with MTF Biologics’ mission of honoring donor families by serving patients who are in need of grafts and allograft solutions to aid them on their road to recovery.”
Orthofix Medical Inc. is a global medical device company with a spine and orthopedics focus. The company’s mission is to deliver quality-driven solutions while partnering with healthcare professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedics products are distributed in more than 60 countries via the company's sales representatives and distributors.
MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.
The collaboration extends Orthofix’s exclusive marketing rights to the Trinity allograft line through 2032 and includes an expansion agreement for the development of a demineralized bone matrix (DBM) that Orthofix will market under the Legacy brand name.
“Together Orthofix and MTF Biologics have a long history of bringing advanced biologic solutions to the market, with more than 350,000 patients receiving their Trinity allografts,” said Orthofix President of Global Spine Kevin Kenny. “This agreement solidifies our partnership with MTF Biologics as the sole provider of MTF allograft offerings. The addition of the Legacy demineralized bone line will expand our biologic portfolio, increasing the options available and offering a value solution for our customers and their patients.”
The Legacy DBM will be a complementary addition to the Orthofix demineralized bone line which consists of FiberFuse Advanced and FiberFuse Strip, both also provided by MTF Biologics. A demineralized cortical bone powder with a sodium hyaluronate carrier, the Legacy DBM will be applicable in spine and orthopedic procedures. The Parties expect to make the Legacy DBM available to customers starting in the third quarter.
Orthofix recognizes the important role of biologic solutions in spine and orthopedic surgical applications. In addition to the MTF Biologics allograft solutions, Orthofix markets and distributes the Opus Mg Set bone void filler, Opus BA bioactive bone graft, Collage osteoconductive scaffold, and the O-Genesis graft deliver system. This portfolio gives surgeons the ability to select the best option to meet their procedural and patient needs.
“MTF Biologics is pleased to strengthen our exclusive partnership with Orthofix to continue our joint investments in innovative solutions, and the provision of Trinity Elite and Trinity Evolution allografts,” said Joe Yaccarino, president and CEO MTF Biologics. “This agreement aligns with MTF Biologics’ mission of honoring donor families by serving patients who are in need of grafts and allograft solutions to aid them on their road to recovery.”
Orthofix Medical Inc. is a global medical device company with a spine and orthopedics focus. The company’s mission is to deliver quality-driven solutions while partnering with healthcare professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedics products are distributed in more than 60 countries via the company's sales representatives and distributors.
MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.